Please assess the completion status of the following clinical trial:

Trial Title: Real World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients receiving at least 11 infusions of natalizumab as disease-modifying monotherapy for RRMS that is consistent with the approved dosing~Exclusion Criteria:~* Patients for whom the NTZ infusion history and/or MRI and clinical history is not available.~* Patients with dosing gap defined as \>=12 weeks between any two doses.~* Patients with over dose defined as \<3 weeks between any two doses.~* Pregnancy during the follow-up period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard Interval Dosing (SID) (Type: None): Patients continuing Natalizumab treatment with standard interval dosing defined as \> 11 infusions per year
- Extended Interval Dosing (EID) (Type: None): Patients switching to extended interval dosing defined as ≤ 10 infusions per year

Based on this trial design, predict the completion outcome and termination type (if applicable).